Symptomatic HIV Seroconverting Illness is Associated with More Rapid Neurological Impairment

Overview

Journal Sex Transm Infect

Specialty Infectious Diseases

Date 2001 Jun 13

PMID 11402229

Citations 8

Authors

M R Wallace

J A Nelson

J A McCutchan

T Wolfson

I Grant

Affiliations

Soon will be listed here.

Abstract

Objectives: To establish whether symptomatic seroconverting illness in HIV infected people is associated with more rapid development of neurological impairment.

Methods: 166 HIV infected subjects with a known date of HIV infection enrolled in a longitudinal study of neurocognitive function were stratified by whether or not they had experienced a symptomatic serconverting illness.

Results: 29 of 166 (17.5%) dated HIV seroconverters had a history of symptomatic seroconverting illness. Though baseline neurocognitive function was similar, subjects with a symptomatic seroconverting illness developed clinical neurocognitive impairment significantly more rapidly than their asymptomatic counterparts in a survival analysis model (636 v 1075 days till impaired).

Conclusion: Symptomatic seroconverting illness predisposes to more rapid neurocognitive impairment.

Citing Articles

HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment.

Eggers C, Arendt G, Hahn K, Husstedt I, Maschke M, Neuen-Jacob E J Neurol. 2017; 264(8):1715-1727.

PMID: 28567537 PMC: 5533849. DOI: 10.1007/s00415-017-8503-2.

[HIV 1-associated neurocognitive disorder: current epidemiology, pathogenesis, diagnosis and management].

Eggers C Nervenarzt. 2014; 85(10):1280-90.

PMID: 25292163 DOI: 10.1007/s00115-014-4082-y.

Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons.

Crum-Cianflone N, Moore D, Letendre S, Poehlman Roediger M, Eberly L, Weintrob A Neurology. 2013; 80(4):371-9.

PMID: 23303852 PMC: 3589242. DOI: 10.1212/WNL.0b013e31827f0776.

Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden.

Spudich S, Gisslen M, Hagberg L, Lee E, Liegler T, Brew B J Infect Dis. 2011; 204(5):753-60.

PMID: 21844301 PMC: 3156103. DOI: 10.1093/infdis/jir387.

Loss of neuronal integrity during progressive HIV-1 infection of humanized mice.

Dash P, Gorantla S, Gendelman H, Knibbe J, Casale G, Makarov E J Neurosci. 2011; 31(9):3148-57.

PMID: 21368026 PMC: 3059783. DOI: 10.1523/JNEUROSCI.5473-10.2011.

References

Gaines H, von Sydow M, Pehrson P, Lundbegh P . Clinical picture of primary HIV infection presenting as a glandular-fever-like illness. BMJ. 1988; 297(6660):1363-8. PMC: 1835053. DOI: 10.1136/bmj.297.6660.1363. View

Niu M, Bethel J, Holodniy M, Standiford H, Schnittman S . Zidovudine treatment in patients with primary (acute) human immunodeficiency virus type 1 infection: a randomized, double-blind, placebo-controlled trial. DATRI 002 Study Group. Division of AIDS Treatment Research Initiative. J Infect Dis. 1998; 178(1):80-91. DOI: 10.1086/515612. View

Schechter M, Craib K, Le T, Montaner J, Douglas B, Sestak P . Susceptibility to AIDS progression appears early in HIV infection. AIDS. 1990; 4(3):185-90. DOI: 10.1097/00002030-199003000-00002. View

Tindall B, Cooper D . Primary HIV infection: host responses and intervention strategies. AIDS. 1991; 5(1):1-14. View

Keet I, Krijnen P, Koot M, Lange J, Miedema F, Goudsmit J . Predictors of rapid progression to AIDS in HIV-1 seroconverters. AIDS. 1993; 7(1):51-7. DOI: 10.1097/00002030-199301000-00008. View

Sinicco A, Fora R, Sciandra M, Lucchini A, Caramello P, Gioannini P . Risk of developing AIDS after primary acute HIV-1 infection. J Acquir Immune Defic Syndr (1988). 1993; 6(6):575-81. View

Clark S, Shaw G . The acute retroviral syndrome and the pathogenesis of HIV-1 infection. Semin Immunol. 1993; 5(3):149-55. DOI: 10.1006/smim.1993.1018. View

Kinloch-De Loes S, de Saussure P, Saurat J, Stalder H, Hirschel B, Perrin L . Symptomatic primary infection due to human immunodeficiency virus type 1: review of 31 cases. Clin Infect Dis. 1993; 17(1):59-65. DOI: 10.1093/clinids/17.1.59. View

Lindback S, Brostrom C, Karlsson A, Gaines H . Does symptomatic primary HIV-1 infection accelerate progression to CDC stage IV disease, CD4 count below 200 x 10(6)/l, AIDS, and death from AIDS?. BMJ. 1994; 309(6968):1535-7. PMC: 2541767. DOI: 10.1136/bmj.309.6968.1535. View

10.

Boufassa F, Bachmeyer C, Carre N, Deveau C, Persoz A, Jadand C . Influence of neurologic manifestations of primary human immunodeficiency virus infection on disease progression. SEROCO Study Group. J Infect Dis. 1995; 171(5):1190-5. DOI: 10.1093/infdis/171.5.1190. View

11.

Henrard D, Daar E, Farzadegan H, Clark S, Phillips J, Shaw G . Virologic and immunologic characterization of symptomatic and asymptomatic primary HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1995; 9(3):305-10. View

12.

Kinloch-De Loes S, Hirschel B, Hoen B, Cooper D, Tindall B, Carr A . A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med. 1995; 333(7):408-13. DOI: 10.1056/NEJM199508173330702. View

13.

Dorrucci M, Rezza G, Vlahov D, Pezzotti P, Sinicco A, Nicolosi A . Clinical characteristics and prognostic value of acute retroviral syndrome among injecting drug users. Italian Seroconversion Study. AIDS. 1995; 9(6):597-604. DOI: 10.1097/00002030-199506000-00011. View

14.

Jolles S, Kinloch de Loes S, Johnson M, Janossy G . Primary HIV-1 infection: a new medical emergency?. BMJ. 1996; 312(7041):1243-4. PMC: 2351063. DOI: 10.1136/bmj.312.7041.1243. View

15.

Schacker T, Collier A, Hughes J, Shea T, Corey L . Clinical and epidemiologic features of primary HIV infection. Ann Intern Med. 1996; 125(4):257-64. DOI: 10.7326/0003-4819-125-4-199608150-00001. View

16.

Bell J, Donaldson Y, Lowrie S, McKenzie C, Elton R, Chiswick A . Influence of risk group and zidovudine therapy on the development of HIV encephalitis and cognitive impairment in AIDS patients. AIDS. 1996; 10(5):493-9. DOI: 10.1097/00002030-199605000-00007. View

17.

Veugelers P, Kaldor J, Strathdee S, Schechter M, Coutinho R, Keet I . Incidence and prognostic significance of symptomatic primary human immunodeficiency virus type 1 infection in homosexual men. J Infect Dis. 1997; 176(1):112-7. DOI: 10.1086/514012. View

18.

Heaton R, Grant I, Butters N, White D, Kirson D, Atkinson J . The HNRC 500--neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc. 1995; 1(3):231-51. DOI: 10.1017/s1355617700000230. View

19.

Vanhems P, Lambert J, Cooper D, Perrin L, Carr A, Hirschel B . Severity and prognosis of acute human immunodeficiency virus type 1 illness: a dose-response relationship. Clin Infect Dis. 1998; 26(2):323-9. DOI: 10.1086/516289. View

20.

Pedersen C, Lindhardt B, Jensen B, Lauritzen E, Gerstoft J, Dickmeiss E . Clinical course of primary HIV infection: consequences for subsequent course of infection. BMJ. 1989; 299(6692):154-7. PMC: 1837064. DOI: 10.1136/bmj.299.6692.154. View